Milrinone Injection
... of glycoside toxicity. Theoretically, in cases of atrial flutter/fibrillation, it is possible that milrinone injection may increase ventricular response rate because of its slight enhancement of AV node conduction. In these cases, digitalis should be considered prior to the institution of therapy of ...
... of glycoside toxicity. Theoretically, in cases of atrial flutter/fibrillation, it is possible that milrinone injection may increase ventricular response rate because of its slight enhancement of AV node conduction. In these cases, digitalis should be considered prior to the institution of therapy of ...
First Degree Heart Block
... May occur in young, otherwise healthy dogs as a manifestation of high vagal tone; “high vagal tone” refers to the vagus nerve—the vagus nerve provides nervous stimulation to the heart, lungs, throat, voice box, windpipe, and gastrointestinal tract; when it is stimulated (known as “vagal tone”), it ...
... May occur in young, otherwise healthy dogs as a manifestation of high vagal tone; “high vagal tone” refers to the vagus nerve—the vagus nerve provides nervous stimulation to the heart, lungs, throat, voice box, windpipe, and gastrointestinal tract; when it is stimulated (known as “vagal tone”), it ...
Treatment of Atrial Fibrillation
... of the heart can cause dizziness, lightheadedness, shortness of breath, weakness and fatigue. Some patients, however, have no sensation that their heart is fibrillating. AF is a dangerous medical condition that becomes more difficult to treat over time and can lead to irreversible heart damage. AF c ...
... of the heart can cause dizziness, lightheadedness, shortness of breath, weakness and fatigue. Some patients, however, have no sensation that their heart is fibrillating. AF is a dangerous medical condition that becomes more difficult to treat over time and can lead to irreversible heart damage. AF c ...
ACLS Drug Overview
... (ANTIARRRHYTHMIC) Used in a wide variety of arrhythmias. Non-arrest dose: 20-50 mg/min. End points: Maxinum dose of 17 mg/kg (1.2 Gm for 70 kg patient), or QRS widens 50%, hypotension, control of arrhythmia. Note: may cause torsades de pointes with QRS widening and prolong QT intervals. Drip: 1 Gm/2 ...
... (ANTIARRRHYTHMIC) Used in a wide variety of arrhythmias. Non-arrest dose: 20-50 mg/min. End points: Maxinum dose of 17 mg/kg (1.2 Gm for 70 kg patient), or QRS widens 50%, hypotension, control of arrhythmia. Note: may cause torsades de pointes with QRS widening and prolong QT intervals. Drip: 1 Gm/2 ...
Arrhythmias: Hyperfunction
... PR Interval: time the electrical impulse takes to travel from the sinus node to the AV node where it enters the ventricles. The PR interval is a good estimate of AV node function. ...
... PR Interval: time the electrical impulse takes to travel from the sinus node to the AV node where it enters the ventricles. The PR interval is a good estimate of AV node function. ...
Here
... • Heart failure is a complex clinical syndrome that can result from any structural or functional cardiac di d th disorder thatt iimpairs i th the ability bilit off th the ventricle t i l tto fill with or eject blood. • HF is not equivalent to cardiomyopathy or to LV dysfunction; these latter terms d ...
... • Heart failure is a complex clinical syndrome that can result from any structural or functional cardiac di d th disorder thatt iimpairs i th the ability bilit off th the ventricle t i l tto fill with or eject blood. • HF is not equivalent to cardiomyopathy or to LV dysfunction; these latter terms d ...
GOG 0281: A RANDOMIZED PHASE II/III STUDY TO ASSESS THE
... 12. Patients with a history or evidence of cardiovascular risk, including any of the following: LVEF 480 msec.
History or evidence of current clinically significant uncontrolled arrhythmias.
Exception: Subjects with controlled atrial fibrillation for > 30 days prior to randomizati ...
... 12. Patients with a history or evidence of cardiovascular risk, including any of the following: LVEF
Management of Chronic Heart Failure in General
... ii. Patients with AF and any degree of heart failure ...
... ii. Patients with AF and any degree of heart failure ...
first aid - essentialsguides
... Step-by-step guide for the new CPR 7. Pinch closed the nose of the victim. Take a normal breath, cover the victim's mouth with yours to create an airtight seal, and then give two, onesecond breaths as you watch for the chest to rise. ...
... Step-by-step guide for the new CPR 7. Pinch closed the nose of the victim. Take a normal breath, cover the victim's mouth with yours to create an airtight seal, and then give two, onesecond breaths as you watch for the chest to rise. ...
8 Pulseless Electrical Activity
... to the prescence of organized electrical activity in the absence of synchronous myocardial contraction (1–3). As such, electrical activity was detected on the surface electrocardiogram but no effective cardiac output was present owing to the absence of coupled mechanical activity. The clinical resul ...
... to the prescence of organized electrical activity in the absence of synchronous myocardial contraction (1–3). As such, electrical activity was detected on the surface electrocardiogram but no effective cardiac output was present owing to the absence of coupled mechanical activity. The clinical resul ...
DDD Pacemaker Implantation in A Patient with Congenitally
... which it was found that he had no inferior vena cava (IVC) draining into the right atrium (RA). Venogram showed venous drainage into the superior vena cava (SVC) from a dilated azygos vein (Fig A). Accordingly, the electrode was positioned in the right-sided ventricle via the azygos vein and SVC. Ec ...
... which it was found that he had no inferior vena cava (IVC) draining into the right atrium (RA). Venogram showed venous drainage into the superior vena cava (SVC) from a dilated azygos vein (Fig A). Accordingly, the electrode was positioned in the right-sided ventricle via the azygos vein and SVC. Ec ...
Rapid Heartbeat - Heart Rhythm Society
... and common. During intense exercise or emotional distress, a heart may speed up to 160 to 180 or more beats per minute. This rapid heart rate is normal and appropriate, and does not pose any danger. ...
... and common. During intense exercise or emotional distress, a heart may speed up to 160 to 180 or more beats per minute. This rapid heart rate is normal and appropriate, and does not pose any danger. ...
depolarization waves.
... could obviously not so return (because of the refractory period); but if conduction were blocked in certain areas, one could conceive of such a "circus" route. ...
... could obviously not so return (because of the refractory period); but if conduction were blocked in certain areas, one could conceive of such a "circus" route. ...
Classes of Drugs Used to Treat Myocardial Infarction
... of distribution and shorter elimination half-life (13-19 hr); Class I, II, III & IV actions; containdicated in severe or recently decompensated, symptomatic heart failure; based on results from atrial fibrillation (nondronedarone the PALLAS trial in 2011, the FDA has concluded there are permanent) a ...
... of distribution and shorter elimination half-life (13-19 hr); Class I, II, III & IV actions; containdicated in severe or recently decompensated, symptomatic heart failure; based on results from atrial fibrillation (nondronedarone the PALLAS trial in 2011, the FDA has concluded there are permanent) a ...
Dysrhythmias
... The major problem with the tachy dysrhythmias is that the heart chambers do not have enough time to completely fill or empty. This leads to a drop in stroke volume and subsequently cardiac output. Depending on the exact rhythm, there may also be loss of synchrony between atrial and ventricular contr ...
... The major problem with the tachy dysrhythmias is that the heart chambers do not have enough time to completely fill or empty. This leads to a drop in stroke volume and subsequently cardiac output. Depending on the exact rhythm, there may also be loss of synchrony between atrial and ventricular contr ...
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS)
... Clinical manifestations of RV HF were detected in 5% of patients in group 1 and 84% in group 2, hydrothorax only in patients of group 2 (13%). Radiographic signs of venous stasis in the pulmonary circulation were determined in 62% of patients in group 1 and 100% - in 2 groups. Cardiothoracic index w ...
... Clinical manifestations of RV HF were detected in 5% of patients in group 1 and 84% in group 2, hydrothorax only in patients of group 2 (13%). Radiographic signs of venous stasis in the pulmonary circulation were determined in 62% of patients in group 1 and 100% - in 2 groups. Cardiothoracic index w ...
After the heart attack: Injectable gels could prevent
... the animals' hearts still showed improvement compared with untreated animals. Based on those findings, a handful of labs are now experimenting with hydrogel treatments, including two materials that are in clinical trials. Neither is from Burdick's lab, but as he notes, "It's important we all keep mo ...
... the animals' hearts still showed improvement compared with untreated animals. Based on those findings, a handful of labs are now experimenting with hydrogel treatments, including two materials that are in clinical trials. Neither is from Burdick's lab, but as he notes, "It's important we all keep mo ...
Cardiac Arrhythmia and Catheter Ablation UK
... 140,000 EU patients are estimated to receive catheter ablation with the number projected to increase to 200,000 by 2019. 22 This underlines the growing impact of cardiac arrhythmias and the need for state-ofthe-art catheter and cardiac mapping technology to improve diagnosis and treatment of all typ ...
... 140,000 EU patients are estimated to receive catheter ablation with the number projected to increase to 200,000 by 2019. 22 This underlines the growing impact of cardiac arrhythmias and the need for state-ofthe-art catheter and cardiac mapping technology to improve diagnosis and treatment of all typ ...
Improved outcome with repeated intracoronary injection of bone
... failure. Our own randomized, cross-over trial showed a significant, albeit modest improvement by absolute 3% in left ventricular ejection fraction (LVEF) at 3 months after intracoronary infusion of bone marrow-derived cells, but no change in the control group.7 In a smaller, non-randomized Danish tr ...
... failure. Our own randomized, cross-over trial showed a significant, albeit modest improvement by absolute 3% in left ventricular ejection fraction (LVEF) at 3 months after intracoronary infusion of bone marrow-derived cells, but no change in the control group.7 In a smaller, non-randomized Danish tr ...
Inversion time prolongation at late enhancement cardiac MRI in a
... he continuous development and improvement of anticancer treatments has led to an increase in life expectancy of oncologic patients. However, several adverse effects associated with chemotherapy drugs are known to counterbalance this favorable outcome. Among the side effects, one of the most severe, ...
... he continuous development and improvement of anticancer treatments has led to an increase in life expectancy of oncologic patients. However, several adverse effects associated with chemotherapy drugs are known to counterbalance this favorable outcome. Among the side effects, one of the most severe, ...
ECG Presentation
... Should be narrow (<120msec) if bundles working properly Then have REPOLARIZATION = Twave ...
... Should be narrow (<120msec) if bundles working properly Then have REPOLARIZATION = Twave ...
Cardiology Terminology Quiz by Laura King, MA, ELS
... and Molecular Cardiology, pp 562-563 in print). 11. Values for LVEF were categorized into 2 groups: normal to mild dysfunction (LVEF ≥0.40) and moderate to severe dysfunction (LVEF <0.40). ANSWER: Values for left ventricular ejection fraction (LVEF) were categorized into 2 groups: normal to mild dys ...
... and Molecular Cardiology, pp 562-563 in print). 11. Values for LVEF were categorized into 2 groups: normal to mild dysfunction (LVEF ≥0.40) and moderate to severe dysfunction (LVEF <0.40). ANSWER: Values for left ventricular ejection fraction (LVEF) were categorized into 2 groups: normal to mild dys ...
AV Nodal Blocks - Cardiac and Stroke Networks in Lancashire
... more P waves to QRS 2 : 1 – Constant PR Interval with more P waves to QRS 3º - Complete dissociation between P waves & QRS ...
... more P waves to QRS 2 : 1 – Constant PR Interval with more P waves to QRS 3º - Complete dissociation between P waves & QRS ...
Cardiac contractility modulation
.jpg?width=300)
Cardiac contractility modulation (CCM) is a treatment for patients with moderate to severe left ventricular systolic heart failure (NYHA class II–IV). The short- and long-term use of this therapy enhances both the strength of ventricular contraction and the heart’s pumping capacity. The CCM mechanism is based on stimulation of the cardiac muscle by non-excitatory electrical signals (NES). CCM treatment is delivered by a pacemaker-like device that applies the NES, adjusted to and synchronized with the electrical action in the cardiac cycle.In CCM therapy, electrical stimulation is applied to the cardiac muscle during the absolute refractory period. In this phase of the cardiac cycle, electrical signals cannot trigger new cardiac muscle contractions, hence this type of stimulation is known as a non-excitatory stimulation. However, the electrical CCM signals increase the influx of calcium ions into the cardiac muscle cells (cardiomyocytes). In contrast to other electrical stimulation treatments for heart failure, such as pacemaker therapy or implantable cardioverter defibrillators (ICD), CCM does not affect the cardiac rhythm directly. Rather, the aim is to enhance the heart’s natural contraction (the native cardiac contractility) sustainably over long periods of time. Furthermore, unlike most interventions that increase cardiac contractility, CCM is not associated with an unfavorable increase in oxygen demand by the heart (measured in terms of Myocardial Oxygen Consumption or MVO2). This may be explained by the beneficial effect CCM has in improving cardiac efficiency. A meta-analysis in 2014 and an overview of device-based treatment options in heart failure in 2013 concluded that CCM treatment is safe, that it is generally beneficial to patients and that CCM treatment increases the exercise tolerance (ET) and quality of life (QoL) of patients. Furthermore, preliminary long-term survival data shows that CCM is associated with lower long-term mortality in heart failure patients when compared with expected rates among similar patients not treated with CCM.